GOODYCE

Goodyce is a South Korean biotechnology company specializing in the development of next-generation exosome-based therapeutics and drug delivery systems. The company utilizes its proprietary Exo-Target platform to engineer extracellular vesicles (EVs) for precision drug delivery, aiming to overcome the limitations of traditional delivery systems such as high immunogenicity and low targeting efficiency. Their research and development pipeline primarily focuses on oncology, inflammatory conditions, and metabolic disorders like NASH. By leveraging the natural biocompatibility of exosomes, Goodyce aims to establish a robust portfolio of precision medicines that offer enhanced safety and efficacy. The company was founded in 2020 as a spin-off from research conducted at the Pohang University of Science and Technology (POSTECH).